Rolipram, a prototypic phosphodiesterase-4 inhibitor, is highly effective in suppressing Th1 autoimmunity in multiple animal models, including experimental autoimmune encephalomyelitis. In addition, rolipram has been extensively studied as a potential neuroprotective agent. Based on its anti-inflammatory activity, we tested the efficacy of rolipram in suppressing inflammatory disease activity in multiple sclerosis in a proof-of-principle phase I/II open-label clinical trial. Enrolled MS patients were evaluated by monthly MRI and clinical examinations during 3 months (four MRIs) of pretreatment baseline and 8 months of rolipram therapy. The primary outcome was a change in contrast-enhanced lesions between baseline and the last 4 months of rolipram therapy. Previously defined biomarkers of rolipram-mediated immunomodulation were evaluated during the study. The trial was stopped prematurely because the drug was poorly tolerated and because of safety concerns: we observed an increase, rather than decrease, in the brain inflammatory activity measured by contrast-enhanced lesions on brain MRI. At the administered doses rolipram was active in vivo as documented by immunological assays. We conclude that the reasons underlying the discrepancy between the therapeutic efficacy of rolipram in experimental autoimmune encephalomyelitis versus multiple sclerosis are at present not clear.
Introduction
Cyclic nucleotides, especially cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), are important as second messengers in cell signaling. In the cells of the immune system, increased intracellular levels of cAMP activate protein kinase A (PKA), which is a potent inhibitor of the immune system. 1 Intracellular cAMP levels are regulated by G-protein-coupled receptors, adenylyl cyclases (ACs) and phosphodiesterases (PDEs). In immune cells, cAMP is cleaved predominantly by phosphodiesterases 4 (PDE-4) and 3 (PDE-3). 2, 3 Therefore, agents that block PDE-4 increase intracellular cAMP levels and subsequently modulate immune functions such as T-cell activation and cytokine secretion. [3] [4] [5] [6] One well-studied PDE-4 inhibitor is rolipram; a drug initially developed based on its antidepressant properties. In-vitro inhibition of PDE-4 by rolipram decreases production of Th1-like cytokines such as tumor necrosis factor alpha (TNF-a) and interferon gamma (INF-g) by activated human T-cells. [5] [6] [7] Consistent with these changes, studies of PDE-4 inhibitors in several models of experimental autoimmune encephalomyelitis (EAE) have shown a beneficial effect on disease activity. 6, [8] [9] [10] [11] [12] [13] [14] In addition, PDE-4 inhibitors ameliorated disease in a variety of other experimental autoimmune diseases, such as experimental autoimmune uveitis, 15 collagen-induced arthritis 16, 17 and diabetes in the non-obese diabetic (NOD) mouse. 18 In all of these animal models, T-cells of Th1 or, as documented much later, Th17 phenotype underlie immunemediated tissue destruction. Based on observations indicating that Th1 cells can be encephalitogenic in humans, 19 we reasoned that PDE-4 inhibitors such as rolipram might block inflammatory disease activity in multiple sclerosis (MS).
The current report describes the results of a phase I/early phase II clinical study of rolipram in MS. As will be described, the study was terminated early because of tolerability reasons and lack of efficacy.
Materials and methods

Clinical trial design
Rolipram raw material, as well as toxicity and pharmacology data, were made available to the principal investigator of the study (R Martin), Cellular Immunology Section, Neuroimmunology Branch (NIB) of the National Institutes of Neurological Disorders and Stroke (NINDS), NIH, by Schering AG, Berlin, Germany, under a Collaborative Research and Development Agreement (CRADA). Recrystallization, regulatory application for a FDA IND (# 60,932) and part of the trial were supported by an NINDS intramural Bench-to-Bedside grant. Rolipram was recrystallized from the raw material under GMP conditions by an independent contractor and packed into capsules by the NIH pharmacy.
The main purpose of this open-label, baselineversus-treatment clinical trial was to test the safety, tolerability and effects of rolipram on brain inflammatory activity in MS patients. The trial consisted of two stages ( Figure 1 ). Stage I was a safety-and dose-finding study in six patients with definite relapsing-remitting (RR) or secondary-progressive (SP) MS 20 with moderate disability (Expanded Disability Status Scale (EDSS 21 4.0-6.5; EDSS of 0 meaning without neurological deficit and EDSS of 10 meaning death from MS), who had no or low brain inflammatory activity. These patients are identified by codes R101-R106.
The Stage II study (initiated after four out of six patients in Stage I finished the dose-escalation phase, and safety and tolerability data were collected) stipulated up to 20 RR or SP MS patients with EDSS 1.5-6.5 and moderate brain inflammatory activity (average at least 0.5 contrast-enhanced lesions (CELs) per scan during four monthly pre-treatment MRI scans). Only two patients were enrolled and completed dosing (R201-R202) before the trial was terminated ( Figure 1 ).
Enrolment criteria included that patients had to be off treatment at baseline: could not tolerate FDAapproved disease-modifying therapies or chose not to be treated or their neurologist referred them to the trial because they had not responded to prior treatment. Prior treatment in patients was as follows: interferon beta (IFN-b) in patients R101, R102, R103, R105 and R202; glatiramer acetate (GA) in patient R101; intravenous steroids in R102 and R104; bee-sting therapy in R103; no prior therapy in patients R106 and R201. All patients were at least 1 year beyond prior therapy. Both groups underwent rolipram dose escalation during the first 28 days according to a pre-determined dosing schedule ( Figure 1 ). While patients in Stage I were dosed up to 9 mg/day (3 mg, three times daily), patients in Stage II were dosed only up to 7.5 mg/day, which was selected as the highest tolerable dose based on the results of Stage I. Patients were followed by monthly MRI and clinical examinations ( Figure 1 and Table 1 ). The primary outcome measure was inhibition of brain inflammatory activity measured as CELs on brain MRI during the last 4 months of Rolipram therapy (months 5-8) compared with the 4 months of pre-treatment baseline (months -3 to 0). Secondary outcome measures were changes in volumetric MRI parameters (see the MRI collection and analysis section) and clinical parameters (EDSS, 21 Scripps Neurologic Rating Scale (NRS) 22 and MS Functional Composite score (MSFC) 23 ) as defined in Table 1 , comparing the same treatment periods. The trial design was approved by the NINDS Institutional Review Board (IRB), and all patients signed the informed consent. Safety and tolerability were assessed by an independent data and safety monitoring board (DSMB). 19 CELs were recorded on hardcopy films by consensus of two radiologists. T2LV was determined by a semi-automated thresholding technique (PV-WAVE). 24 The volume of CELs was determined from registered images 25 using a semiautomated thresholding program (Jeff Solomon, MRIPS, NIH) on MEDX (Sensor Systems, Sterling, VA) applied to post-contrast T1WI, after verification of lesion co-localization on T2WI or FLAIR images. Brain parenchymal fraction (BPF) was determined on registered, pre-contrast T1W images using the automated program (ADPK mean) as described previously. 26 
Prospective immunophenotyping by flow cytometry
Blood samples (10 cc of ethylenediaminetetraacetic acid (EDTA) anti-coagulated blood) were collected bi-monthly between 8:30 and 11:30 a.m. and were processed within 2 h. Surface markers were evaluated from fresh cells prospectively by 3-4 color flow cytometry using commercially available fluorescent antibodies (Ab) after RBC lysis as described previously. 27 The absolute numbers of CD4+ and CD8 +T-cells and CD19+ B-cells and CD14+ monocytes were calculated from application of percentages of these cells derived from flow-cytometry analyses to absolute numbers of lymphocytes, determined by the NIH Clinical Center laboratory from parallel whole blood samples.
Additional assays from cryopreserved peripheral blood mononuclear cells
Lymphocytapheresis was collected during baseline, at months three and eight of Rolipram therapy between 8:30 and 11:30 a.m. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradients within 2 h of ex-vivo collection and were cryopreserved. For monocytes and B-cell activation assay, PBMCs from baseline and rolipram therapy samples were thawed and processed simultaneously. B-cells (CD3 -/ CD19+ lymphocytes) and monocytes (CD14+) in thawed PBMC cultures were stained for the surface expression of CD80 and CD86 immediately after thawing and 20 h after activation with lipopolysaccharide (LPS; 1 mg/ml) and analyzed by flow cytometry. Upregulation of CD80 expression on activated B-cells and monocytes was compared between baseline and therapy samples.
For CFSE proliferation assay, PBMCs were stained with 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen; 1 mM) as described previously. 28 After washing, PBMCs at a density of 1 Â 10 6 PBMC/ml were activated with plate-bound anti-CD3 (20 ng/ml; pre-incubated at 37 C for 2 h) and CD28 (at 10 mg/ml). Six days post-stimulation, cells were stained for surface population markers and analyzed by flow cytometry. We calculated the total number of mitoses per 100 gated cells using the formula: number of mitoses ¼ R (X n Â 100 -X n Â 100/2 n ), where X is the percentage of cells that underwent n divisions.
Statistical analysis
Changes in clinical and MRI measures between baseline, treatment and post-treatment were assessed by Friedman Repeated Measures Analysis of Variance on Ranks. For categorical data (adverse events) Fisher's exact test was used. In order to evaluate immunological changes from baseline to treatment, two baseline samples and two or three treatment samples were averaged for each individual and compared by Signed Rank Test or, if permitted, by paired t-test. All statistics were performed using Sigma-Stat 3.5 (Jandel Scientific, CA), with a pre-set limit of statistical significance of p < 0.05.
Results
Safety and tolerability
Rolipram therapy was poorly tolerated, but it did not lead to significant changes in clinical measures of disability.
During the pre-treatment baseline we observed a total of 10 adverse events (AEs; 3.63 per patient-year; Table 1 ); all of them were grades 1-2 (NCI Common Terminology Criteria for Adverse Events; http:// ctep.info.nih.gov). The total number of AEs increased to 8.08 per patient-year during rolipram therapy (223%; p ¼ 0.01, Fischer's exact test); all of them were grades 1-2 except two, which were grade 3 (atypical hypersensitivity reaction to rolipram in patient R105, which led to discontinuation of rolipram after 4 months of treatment, and severe insomnia, gastroesophageal reflux and balance changes in patient R106 resulting in her withdrawal from the trial after three months of treatment). The number of infections increased from 0.73 per patient-year during baseline to 1.97 per patient-year during rolipram therapy (269%; not significant). We observed three exacerbations during baseline (1.09 per patient-year) and six exacerbations during rolipram treatment (1.31 per patient-year). The remaining adverse events observed during rolipram therapy were most commonly nausea, vomiting and insomnia.
With respect to the dose-finding phase, only two (R102 and R104) out of six Stage I patients could be titrated to the highest stipulated dose of 3 Â 3 mg/day, and in one (R104) the dose had to be reduced to 3 Â 2.5 mg/day due to recurrent headache and fatigue, which we attributed to rolipram. There was no significant difference in the number of reported AEs in these two and all remaining patients.
We saw no significant changes in the clinical measures of disability; they all remained stable or slightly improved ( Table 1 ).
Primary outcome measure
Rolipram therapy increased the number of CELs on brain MRI.
Besides the poor tolerability, the main concern of the investigators and the DSMB was the increase in CELs observed during rolipram therapy (Table 1) , which was especially evident during the latter half of the treatment period ( Figure 2C ). According to pre-determined analyses (i.e. comparing 4 months of pre-treatment baseline with the last 4 months of rolipram therapy; Figure 2C , darker shaded area: months 5-8; only six patients who concluded the 8 months of dosing are included), the total number of CELs per patient per month increased from a median of 0.44 to a median of 1.00 (227.3%; p ¼ 0.052) at the time when the investigators in consultation with the DSMB decided to terminate the trial early. As is evident from the data of individual patients (Figure 2A and B) , the total number of CELs increased during the last 4 months of rolipram therapy in three out of six patients in Stage I (two of the six patients stopped rolipram dosing before month 5 and one patient had no CELs during the entire trial) and in two out of two patients in Stage II as compared to pre-treatment baseline periods.
The volume of CELs also increased from a median of 0.008 cm 3 to 0.023 cm 3 (287.5%). T2 lesion load (T2LL) values remained unchanged. Although we observed a non-significant increase in BPF during rolipram therapy, this was more likely due to edema associated with the increased CELs than to stabilization or reversal of brain atrophy.
In order to provide data on the entire cohort, Table 1 includes, in addition to pre-determined analyses, also MRI and clinical data for all patients during the entire treatment period.
Ex-vivo immunophenotyping of B-cells, T-cells and monocytes
In our in-vitro studies 5 we identified several effects of rolipram on the human immune system, which we used as biomarkers to monitor in-vivo biological activity of rolipram during the current trial. Among these were the induction of CD86 expression on B-cells and inhibition of CD80 expression on LPS-activated B-cells and monocytes. By ex-vivo immunophenotyping performed prospectively every 2 months during the trial, we observed a statistically significant increase in the percentage of CD86+ (but not CD80+) B-cells during rolipram therapy ( Figure 3A) . Similarly, we observed a statistically significant inhibition of surface CD80 upregulation on LPS-activated B-cells and monocytes during rolipram therapy ( Figure 3B ).
In addition, we observed changes in the prospectively acquired immunophenotyping data that were not predicted from our in-vitro experiments: we observed a mild, but statistically significant, decrease in the percentage and absolute numbers of monocytes and CD4+ T-cells during rolipram therapy ( Figure 3C ), although none of these values fell outside the normal range.
Inhibition of T-cell proliferation ex-vivo during Rolipram treatment
Our previous in-vitro experiments also demonstrated that rolipram, at the concentrations achievable in vivo (i.e. 0.1 mg/ml), inhibits T-cell proliferation. 5 Therefore, we assessed T-cell proliferation to polyclonal stimuli in cryopreserved PBMCs derived from baseline, month 3 and month 8 of rolipram therapy samples without exogenous addition of the drug. We observed a statistically significant inhibition of CD4+ and CD8+ T-cell proliferation, which was more robust at a later therapy time-point (month 8) (Figure 4 ).
Discussion
Rolipram, a prototypical PDE-4 inhibitor, represented a highly attractive therapy for MS based on several criteria: first, it had a beneficial therapeutic effect on multiple EAE models, in both prevention and treatment paradigms. 6, [8] [9] [10] [11] [12] [13] [14] Second, it was later also shown to have neuroprotective properties, [29] [30] [31] and finally, at the time when this trial was initiated, it represented one of the few oral agents with therapeutic potential for MS. 32 Despite the wealth of promising data, the present proof-of-principle clinical trial of rolipram in MS had to be stopped based on the poor tolerability of rolipram and the lack of efficacy or possibly even an increase in inflammatory activity as measured by MRI. When the changes in total CELs/month during the 4 months of baseline were compared with the last 4 months on therapy, an increase during the treatment phase was noted and, despite the small number of patients, this increase nearly reached statistical significance (225% increase; p ¼ 0.052). An increase in the number and/or volume of CELs during rolipram treatment was observed in six out of eight individuals (the two remaining individuals had no inflammatory lesions during the entire trial). Also, in two patients with active disease (Stage II patients) the level of activity appeared greater in the treatment phase than would have been predicted from the level of activity during the baseline evaluation. With the type of trial design that was used here, it is expected that, if the drug has no effect on MS inflammatory activity, the number of CELs will remain stable or even decrease (due to regression to the mean) during treatment as compared with baseline. This notion is underlined by our prior experiences with an identical trial design. We never observed an increase in CELs during treatment in eight different trials with five different therapies at the group level 19, [33] [34] [35] [36] (and unpublished observations). In view of these data, the observed increase in CELs during the therapeutic phase of this trial was cause for concern, even though it was not accompanied by clinical deterioration. However, because of the small number of patients, it is impossible to conclude with a high level of confidence that rolipram increases inflammatory disease activity in MS. Also consistent with an accentuation of disease is the small increase in the number of exacerbations adjusted for exposure. However, again, the small number of patients requires that these changes be regarded with caution.
What could explain a lack of effect or even an increase in inflammatory activity in MS when previous studies in EAE have shown a prominent anti-inflammatory action of the drug? Our immunological data clearly indicate that rolipram was pharmacologically active in vivo, and the observed increase of CD86 expression on resting B-cells as well as the decrease of CD80 expression on activated B-cells and monocytes is consistent with our prior in-vitro studies. Finally, we observed a reduced proliferative capacity of CD4+ and CD8+ T-cells derived from Rolipram therapy samples as compared with pre-treatment PBMC samples. All of these biomarker analyses were predetermined and based on our prior data on the in-vitro effects of rolipram on human immune cells. 5 We observed two additional changes that were not predicted from in-vitro studies. Rolipram treatment resulted in a mild decrease in blood monocytes and CD4+ T-cells. Since rolipram is highly lipid soluble and rapidly passes the blood-brain barrier, it is expected that its immunomodulatory actions will also occur in the central nervous system compartment. The observations from the current trial show that, despite the many promising findings in animal models and in-vitro studies, inhibition of PDE-4 does not block inflammatory disease activity in MS, which is considered a prototypic Th1-mediated autoimmune disease. We currently do not know whether this discrepancy is due to profound differences in the pathogenesis of EAE versus MS as has been suggested by other failed translations from the model to the human disease or if we did not sufficiently consider factors other than the Th1/Th2 balance such as regulatory immune cells, for example Foxp3+ T cells, 37 interleukin-10-producing T-cells 38 and other regulatory populations such as CD56 bright natural killer cells. 28 Despite the apparent lack of efficacy of rolipram on acute inflammatory activity in MS, the possibility that the drug could contribute to neuroprotection remains. [29] [30] [31] Furthermore, PDE-4 inhibitors have been shown to have immunomodulatory effects that may target events in the MS lesion other than those contributing to blood-brain barrier disruption seen on contrast-enhanced MRI, such as the production of nitric oxide. The current study did not address these issues, but we can conclude at this point that any future use of PDE-4 inhibitors in the treatment of MS must be approached with caution and using studies that are carefully monitored for increase in disease activity. Our experience with rolipram raises an additional important point that should be considered in future neuroprotective trials in MS. In contrast to purely neurodegenerative disorders, the use of neuroprotective agents in MS may be complicated by the effects of these agents on the immune system, which may inadvertently enhance MS-related inflammation, thus limiting their overall therapeutic potential. 
